Status:
COMPLETED
Rivaroxaban Post Coronary Bypass Surgery
Lead Sponsor:
Shiraz University of Medical Sciences
Conditions:
Post Coronary Bypass Surgery Patients
Eligibility:
All Genders
45-87 years
Phase:
PHASE4
Brief Summary
Post coronary bypass patients were randomized to receiving aspirin alone or aspirin and low dose rivaroxaban
Detailed Description
This study is a 1-year randomized, double-blind placebo-controlled trial to evaluate the effects of adding rivaroxaban to the treatment of patients after coronary bypass surgery. All patients referred...
Eligibility Criteria
Inclusion
- Patients older than 18 undergoing primary isolated coronary bypass surgery, with or without cardiopulmonary bypass
Exclusion
- Other cardiac surgeries except for coronary bypass surgery
- Left ventricular ejection fraction \< 30 %
- Liver disease
- Clopidogrel or aspirin intake within 7 days of operation
- Need for perioperative warfarin
- Active gastroduodenal ulcer or post-operative gastrointestinal bleeding
- Profuse post-operative pleural effusion (drainage \>200 ml/h for 2 h or more
- Postoperative low cardiac output syndrome or requirement for high levels of hemodynamic support (more than 2 inotropes for more than 24 h and/or intra-aortic balloon pump)
- Clinical instability, such as perioperative myocardial infarction or malignant tumor.
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 20 2022
Estimated Enrollment :
234 Patients enrolled
Trial Details
Trial ID
NCT06019741
Start Date
February 1 2021
End Date
July 20 2022
Last Update
September 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Professor Kojuri Cardiology Clinic
Shiraz, Fars, Iran, 55318